ATTAC-MCC: Phase I/II study of autologous CD8+ and CD4+ transgenic T cells expressing a high affinity MCPyV-specific TCR combined with checkpoint inhibitors and class I MHC-upregulation in patients with metastatic MCC refractory to PD-1 axis blockade.

Authors

Joshua Veatch

Hutchinson Cancer Rsrch Ctr, Seattle, WA

Joshua Veatch , Ananth Akkiraju , Agus Darwanto , Sean Garrity , Damien Hallet , Kim Nguyen , Piotr Pierog , Tomasz Sewastianik , Markus P Vallaster , Loic Vincent , Aude Chapuis

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2018 ASCO Annual Meeting

bookmark_border

Phase I/II study of the PI3Kβ inhibitor GSK2636771 in combination with pembrolizumab (P) in patients (pts) with PD-1 refractory metastatic melanoma (MM) and PTEN loss.

First Author: Hussein Abdul-Hassan Tawbi

insert_chart_outlined

Poster

2022 ASCO Genitourinary Cancers Symposium

bookmark_border

Attamage-A1: Phase I/II study of autologous CD8+ and CD4+ transgenic t cells expressing high affinity MAGE-A1-specific T-cell receptor (TCR) combined with anti-PD(L)1 in patients with metastatic MAGE-A1 expressing cancer.

First Author: Michael Thomas Schweizer

insert_chart_outlined

Poster

2017 ASCO-SITC Clinical Immuno-Oncology Symposium

bookmark_border

Distinct dominant T-cell receptors with a tissue resident memory phenotype in individual melanoma metastases.

First Author: Kavita M. Dhodapkar

insert_chart_outlined

Poster

2024 ASCO Genitourinary Cancers Symposium

bookmark_border

Final results of a phase I trial of HERV-E TCR transduced T cells for the treatment of HLA-A*11 patients with metastatic clear cell renal cell carcinoma (mccRCC).

First Author: Rosa Nadal